Last updated: October 12, 2026
Homoharringtonine, marketed in the United States as omacetaxine mepesuccinate under the brand Synribo, is an injectable protein-synthesis inhibitor approved for adults with chronic-phase or accelerated-phase chronic myeloid leukemia (CML) who are resistant or intolerant to at least two tyrosine kinase inhibitors (TKIs). Its U.S. commercial opportunity is limited by a narrow label, subcutaneous administration, competition from multiple TKIs, and the absence of a broad first-line role. The principal development opportunity is in China and in investigational combinations for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and selected myeloid malignancies.
The base-case market outlook is stable to declining in U.S. CML and modest growth in China-led hematology use. A material upside scenario requires positive clinical data in combination regimens and broader regulatory approvals.
What is homoharringtonine and how does omacetaxine work?
Homoharringtonine is a cephalotaxine alkaloid originally derived from Cephalotaxus plants. Omacetaxine mepesuccinate is the semisynthetic pharmaceutical form used in Synribo.
Omacetaxine inhibits protein synthesis by binding to the ribosomal A site and interfering with aminoacyl-tRNA positioning. The mechanism is distinct from BCR::ABL1 TKIs. It can reduce production of short-lived oncogenic proteins, including BCR::ABL1 and related signaling proteins. This mechanism provides a rationale for use after TKI resistance or intolerance, including some cases involving BCR::ABL1 mutations.
The drug is administered subcutaneously rather than orally. The U.S. label uses an induction schedule of 1.25 mg/m² twice daily for 14 consecutive days in a 28-day cycle, followed by a maintenance schedule of twice daily dosing for seven days in a 28-day cycle once hematologic response is achieved [1].
Key product attributes
| Attribute |
Omacetaxine mepesuccinate |
| Active substance |
Homoharringtonine |
| U.S. brand |
Synribo |
| U.S. sponsor |
Teva Pharmaceuticals |
| Drug class |
Protein-synthesis inhibitor |
| Route |
Subcutaneous injection |
| U.S. indication |
Chronic-phase or accelerated-phase CML after resistance or intolerance to at least two TKIs |
| FDA approval |
October 26, 2012 |
| Regulatory pathway |
Accelerated approval |
| Main commercial market |
Later-line CML |
| Primary development risk |
Limited use outside heavily pretreated disease |
What is the FDA regulatory status of omacetaxine?
The FDA granted accelerated approval in 2012 based on response data from two single-arm clinical trials involving patients with chronic-phase or accelerated-phase CML who had failed at least two TKIs [1, 2].
The approval was based mainly on major cytogenetic response in chronic-phase CML and major hematologic response in accelerated-phase CML. The label did not establish omacetaxine as a first-line treatment or as a replacement for BCR::ABL1 TKIs.
U.S. exclusivity timeline
| Event |
Date or status |
| FDA approval |
October 2012 |
| Five-year new chemical entity exclusivity |
Expired in 2017 |
| Orphan-drug exclusivity |
Approximately seven years from approval, subject to the approved indication |
| Current regulatory role |
Later-line treatment for selected CML patients |
| Confirmatory-development issue |
The drug’s accelerated-approval framework creates continuing pressure for confirmatory evidence |
| Biosimilar pathway |
Not applicable because omacetaxine is a small-molecule drug, not a biologic |
The drug’s U.S. regulatory position differs from a biologic with reference-product exclusivity. A future competitor would generally pursue an abbreviated new drug application if the product could satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, and injectable-product quality.
What patents protect homoharringtonine and Synribo?
The patent estate has historically covered omacetaxine compositions, pharmaceutical formulations, and methods of treating cancer. The most commercially relevant U.S. patent commonly associated with Synribo is U.S. Patent No. 8,173,858. Patent-term calculations and Orange Book listing status should be assessed against the current FDA database and any applicable patent-term adjustment.
A patent’s existence does not by itself prevent generic entry. The commercial effect depends on:
- Whether the patent is listed in the Orange Book.
- The listed expiration date.
- Whether the patent claims the approved product, a formulation, or a method of use.
- Whether an ANDA applicant files a Paragraph IV certification.
- Whether the NDA holder brings infringement litigation within the statutory period.
- Whether a court upholds the patent.
Patent categories relevant to omacetaxine
Composition patents
Composition claims can cover homoharringtonine, omacetaxine salts, stereochemical forms, crystalline forms, or pharmaceutical-grade derivatives. These claims provide the broadest exclusionary scope but are usually the earliest patents in the lifecycle and therefore face the greatest expiration pressure.
Formulation patents
Formulation claims may cover the injectable presentation, solvent system, concentration, stability profile, container, or reconstitution procedure. These patents can delay direct competition after composition patents expire, but their enforceability depends on the scope of the asserted claims and the generic product’s formulation.
Method-of-use patents
Method patents may cover treatment of CML after failure of TKIs or particular dosing schedules. They can support a patent litigation strategy even when a generic seeks approval for a narrower, non-patented indication. Skinny-label strategies can reduce the commercial reach of method-of-use protection.
Orange Book status
The FDA Orange Book is the controlling public source for listed patents and exclusivity associated with approved small-molecule products. Synribo’s patent position should be reviewed using the current Orange Book entry rather than relying on historic patent tables. The practical issue is whether any unexpired listed patent remains enforceable against a fully labeled or proposed generic product [3].
When does homoharringtonine lose market exclusivity?
The key U.S. exclusivity periods have already expired or are no longer the principal barrier to entry.
Five-year new chemical entity exclusivity began with the 2012 approval and expired in 2017. Any orphan-drug exclusivity attached to the approved CML indication was limited to the statutory orphan period. Patent protection, rather than regulatory exclusivity, is the more relevant potential barrier for U.S. generic entry.
No biosimilar risk exists because omacetaxine is a chemically synthesized small molecule. The relevant competitive threat is an ANDA-approved generic injection or a competing product using the same active ingredient.
Which companies are challenging omacetaxine?
The principal direct competitive risk is from generic injectable manufacturers rather than from biosimilar developers. Publicly visible competitive pressure has been greater from alternative CML therapies than from a branded homoharringtonine rival.
CML competitors
Omacetaxine competes with several BCR::ABL1 inhibitors:
- Imatinib, marketed by Novartis as Gleevec and available from multiple generic manufacturers.
- Dasatinib, marketed by Bristol Myers Squibb as Sprycel and available generically.
- Nilotinib, marketed by Novartis as Tasigna and available generically in some markets.
- Bosutinib, marketed by Pfizer as Bosulif.
- Ponatinib, marketed by Takeda as Iclusig.
- Asciminib, marketed by Novartis as Scemblix.
Asciminib is especially important strategically because it is designed to bind the myristoyl pocket of BCR::ABL1 and has expanded treatment options for patients with resistance or intolerance to prior TKIs. Its use may reduce the number of patients reaching omacetaxine in the treatment sequence [4].
No broadly established U.S. Paragraph IV challenge to Synribo is identified in the core FDA regulatory record. This does not establish that no confidential or recently filed challenge exists. A Paragraph IV filing would become commercially important only if supported by a viable ANDA and followed by patent litigation or settlement.
What clinical development is under way for homoharringtonine?
The strongest development activity is outside the original U.S. CML label.
Acute myeloid leukemia
Homoharringtonine has been studied in AML, frequently in combination with cytarabine, anthracyclines, or other agents. Chinese clinical practice and published studies have provided the largest body of experience. The main development questions are:
- Whether the drug improves complete remission rates.
- Whether it improves overall survival after adjustment for patient risk.
- Whether toxicity is acceptable compared with venetoclax-based regimens.
- Whether it has a role in relapsed or refractory AML.
- Whether a biomarker can identify patients most likely to respond.
Venetoclax plus hypomethylating agents has changed the AML treatment market. A homoharringtonine regimen would need either superior efficacy in a defined subgroup, a lower cost, or a practical advantage in a setting where venetoclax combinations perform poorly.
Myelodysplastic syndromes
HHT has also been evaluated in MDS and related myeloid disorders. The commercial opportunity is constrained by the availability of hypomethylating agents, lenalidomide for selected del(5q) disease, targeted therapies, and transplant strategies.
Combination development
Combination studies are more commercially relevant than further development as single-agent salvage therapy. Potential partners include:
- Hypomethylating agents such as azacitidine and decitabine.
- Cytarabine-based chemotherapy.
- Targeted agents directed at FLT3, IDH1, or IDH2.
- BCL-2 inhibitors.
- Other agents used in resistant myeloid malignancies.
The development risk is that combination studies may produce activity without generating a registration-quality treatment advantage. Small, single-arm studies are unlikely to support major international expansion without confirmatory randomized data.
How strong is the patent estate for homoharringtonine?
The patent estate is moderate for the legacy U.S. product but less powerful as a long-term growth asset.
| Patent-estate factor |
Assessment |
| Core active ingredient |
Mature asset with significant term erosion |
| U.S. regulatory exclusivity |
Expired or no longer the main barrier |
| Formulation protection |
Potentially useful if listed and claim scope is narrow enough to avoid design-around |
| Method-of-use protection |
Relevant for labeled CML use but vulnerable to skinny-label strategies |
| Manufacturing protection |
Potentially meaningful because botanical sourcing and semisynthesis create quality-control requirements |
| Generic vulnerability |
Moderate to high once enforceable listed patents lapse |
| China protection |
Depends on local filing dates, grant status, term, and formulation or process claims |
| Long-term moat |
More dependent on clinical positioning and supply reliability than on broad exclusivity |
Manufacturing know-how can remain relevant even after patent expiry. Homoharringtonine production requires controlled sourcing or synthesis, impurity management, stereochemical control, analytical standards, and injectable-product manufacturing. These factors can slow entry but generally do not create the same barrier as a valid composition patent.
What manufacturing and supply-chain barriers affect homoharringtonine?
The active ingredient originated from Cephalotaxus species and was historically associated with extraction from plant material. Commercial production has increasingly relied on semisynthetic or controlled pharmaceutical processes.
Key manufacturing risks include:
- Variability in botanical raw materials.
- Low natural abundance of the active alkaloid.
- Impurity and degradation control.
- Consistent salt formation and injectable stability.
- Sterile manufacturing capacity.
- Specialized analytical testing.
- Supply-chain concentration in China and selected Asian manufacturing networks.
These issues may increase the cost and lead time of generic development. They do not eliminate the possibility of competition, particularly if a manufacturer can source a reliable intermediate or develop a validated synthetic route.
How does homoharringtonine compare with competing CML drugs?
| Factor |
Omacetaxine |
Asciminib |
Ponatinib |
Generic TKIs |
| Mechanism |
Protein-synthesis inhibition |
Myristoyl-pocket BCR::ABL1 inhibition |
Pan-BCR::ABL1 inhibition, including T315I |
ATP-site BCR::ABL1 inhibition |
| Route |
Subcutaneous |
Oral |
Oral |
Oral |
| Typical role |
Later-line CML after multiple TKIs |
Resistant or intolerant CML, including later-line use |
Resistant disease, including T315I |
Broad first-line and later-line use |
| Administration burden |
High |
Low |
Low |
Low |
| Main limitation |
Injection, cytopenias, narrow use |
New-product cost and access |
Cardiovascular risk |
Resistance, intolerance, generic competition |
| Commercial threat to HHT |
High |
High |
Moderate to high |
High |
Omacetaxine’s main disadvantage is operational. Patients must receive repeated subcutaneous injections and manage frequent hematologic monitoring. Oral TKIs are easier to prescribe and use, even when their safety profiles require careful monitoring.
What is the commercial outlook and market projection for homoharringtonine?
The market is a niche hematology opportunity rather than a high-growth oncology franchise.
Base-case projection
The U.S. market is likely to remain small and concentrated in heavily pretreated CML. Demand should trend flat to down as:
- More patients receive effective TKIs earlier.
- Asciminib captures resistant or intolerant CML use.
- Generic TKIs reduce treatment costs.
- Clinicians favor oral therapies over injectable salvage treatment.
- The product has no broad first-line or AML indication in the United States.
Upside scenario
The upside case depends on three events:
- Positive randomized data in AML or MDS.
- Regulatory approval in China or another large hematology market for a broader indication.
- A combination regimen that demonstrates a differentiated survival or remission benefit.
China is the most credible geographic growth market because HHT has longer clinical familiarity there and has been studied in AML and other myeloid diseases. Expansion outside China would require evidence that is competitive with venetoclax-based AML regimens and newer targeted treatments.
Downside scenario
The downside case includes:
- U.S. generic injectable entry.
- Continued low commercial investment by the sponsor.
- Failure of combination studies.
- Reduced use after adoption of asciminib and other targeted therapies.
- Supply interruptions or manufacturing-cost inflation.
- Lack of reimbursement for later-line injectable treatment.
Revenue exposure
No reliable public consensus forecast supports a large future revenue base for Synribo. The product’s revenue exposure is concentrated in a small CML population and is vulnerable to generic entry. Any material increase in value would probably come from new AML or MDS approvals rather than from expansion of the existing U.S. CML label.
What patent litigation or settlement agreements affect Synribo?
The publicly material legal issue is the potential interaction between Orange Book-listed patents, ANDA Paragraph IV certifications, and Hatch-Waxman litigation. A generic applicant can challenge listed patents or seek approval with a label that omits patented methods.
A confirmed commercial launch date would depend on:
- The timing of an ANDA filing.
- The certification made for each listed patent.
- Any 30-month stay triggered by timely litigation.
- Court decisions on validity, infringement, and enforceability.
- A settlement agreement, including a possible agreed launch date.
No widely reported settlement has established a major near-term generic launch date for Synribo in the core public record. The absence of a prominent litigation settlement supports a conclusion that current commercial erosion is driven more by therapeutic competition and limited demand than by a known imminent U.S. generic launch.
What generic launch risks exist for homoharringtonine?
The generic launch risk is moderate in the medium term and high after meaningful enforceable patent protection expires.
A generic sponsor would face several technical requirements:
- Demonstrating pharmaceutical equivalence.
- Establishing injectable-product quality.
- Matching the active moiety and salt form.
- Producing reliable impurity and stability data.
- Addressing complex manufacturing controls.
- Navigating any listed formulation or method patents.
- Establishing bioequivalence under FDA requirements applicable to the product.
The small market may reduce the incentive for multiple generic entrants. A single approved generic could still produce substantial price pressure because the branded market is narrow and largely institutional.
Key Takeaways
- Homoharringtonine is marketed in the United States as omacetaxine mepesuccinate, or Synribo.
- FDA approval is limited to adults with chronic-phase or accelerated-phase CML after resistance or intolerance to at least two TKIs.
- U.S. regulatory exclusivity has expired; patent listing and enforceability are the main remaining legal questions.
- The product has no biosimilar risk because it is a small molecule.
- Generic risk is linked to injectable-product complexity, Orange Book patents, and the limited size of the market.
- Asciminib, generic TKIs, ponatinib, and other targeted agents constrain U.S. growth.
- China and AML/MDS combinations offer the principal development upside.
- The base-case market projection is niche, stable to declining in the United States, with selective growth possible in China.
- A major valuation re-rating would require successful randomized combination data and regulatory expansion beyond later-line CML.
FAQs
Is homoharringtonine the same drug as omacetaxine?
Homoharringtonine is the active alkaloid. Omacetaxine mepesuccinate is the pharmaceutical salt and approved drug form used in Synribo.
Is omacetaxine still used for chronic myeloid leukemia?
Yes. Its U.S. label covers adults with chronic-phase or accelerated-phase CML who are resistant or intolerant to at least two TKIs, although use is limited compared with oral targeted therapies.
Can a generic manufacturer make an omacetaxine injection?
Potentially. A generic applicant would need to satisfy FDA requirements for an injectable ANDA and address any unexpired Orange Book-listed patents, formulation issues, and manufacturing controls.
Does omacetaxine have biosimilar competition?
No. Biosimilars apply to biological products. Omacetaxine is a chemically synthesized small-molecule drug, so any direct competitor would generally use the generic-drug pathway.
What would most increase the value of homoharringtonine?
The strongest value driver would be a registration-quality AML or MDS indication, particularly for a combination regimen that demonstrates a clear survival or remission advantage against current standards of care.
References
- U.S. Food and Drug Administration. (2012). Synribo (omacetaxine mepesuccinate) prescribing information.
- U.S. Food and Drug Administration. (2012). FDA approves Synribo for chronic myeloid leukemia.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2021). Scemblix (asciminib) prescribing information.